Takotsubo cardiomyopathy is a rare complication of electroconvulsive therapy (ECT), an effective and safe treatment for severe depression and psychosis ([@R1]). It has been suggested that catecholamines play a role in takotsubo cardiomyopathy development ([@R2]).

Case report
===========

A 40-year-old white man, severely addicted to nicotine and caffeine, without alcohol misuse history, was admitted to our psychiatry department in December 2017 due to positive psychotic symptoms and was prescribed haloperidol (30 mg/d), promazine (300 mg/d), and diazepam (30 mg/d). He and his family members denied the history of medical conditions, and no medical data on his earlier treatment were found in our hospital's archives. Three weeks later, because of treatment resistance, haloperidol and promazine were discontinued, and clozapine was augmented to a final dose of 350 mg a day. On the sixth day of clozapine therapy, the patient developed tachycardia and was given propranolol (40 mg/d) for cardioprotection. As psychosis did not improve by the end of the week 8, ECT was indicated.

Informed consent and ethical approval for ECT application were obtained from the University Hospital Centre Zagreb. The patient also signed informed consent for medical data publication. Somatic and psychiatric pre-evaluation revealed no contraindications for ECT. The blood pressure was 110/70 mm Hg, heart rate 92/min, axillary temperature 36.0°C, and electrocardiogram (ECG) showed a sinus rhythm with intermediate axis without any abnormalities. ECT was first applied at week 10. Diazepam was discontinued. Atropine, propofol, and succinylcholine were administered as standard premedication. The electrical dose was titrated to the patient's seizure threshold at 0.5-millisecond pulse width, 20-Hz frequency, 5.6-second stimulus duration, and 900-mA current using Thymatron® System IV (Somatics LLC, Chatham, IL, USA), and bifrontotemporal stimulation was applied. Two hours after ECT, the patient complained of gastric pain. He was pale and tachypnoic, without a palpable radial pulse. Initial laboratory tests showed the troponin T level of 1956 ng/L (reference range \<14 ng/L) and N-terminal pro-b-type natriuretic peptide (NT-pro BNP) of 12 409ng/L (reference range \<300 ng/L). ECG showed marked ST-elevation, with Q waves and deep symmetrical T wave inversion in anterior leads, along with QTc interval prolongation (525 ms), indicating possible acute anterior wall myocardial infarction. However, the patient denied chest pain and complained of shortness of breath. The echocardiographic exam revealed severely reduced left ventricle ejection fraction (15%), with only lateral wall contracting and a consequent apical thrombus. The patient was immediately transferred to the Coronary Care Unit, where he was treated with continuous intravenous infusion of dobutamine (4 µg/min/kg) and furosemide (250 mg/d). Beside these, loading doses of aspirin (300 mg) and clopidogrel (600 mg), and low molecular weight heparin in full dose, were administered as standard therapy for suspicious acute myocardial infarction before planned coronarography. Clozapine was discontinued, and haloperidol (30 mg/d) and diazepam (30 mg/d) were induced intramuscularly. The patient refused the recommended coronary angiography and was distrustful to all other proposed diagnostic procedures. After 24 hours, he was hemodynamically stable, and inotropic support was gradually stopped. Heart failure therapy, consisting of eplerenone (25 mg/d) and ivabradine (2 × 5 mg/d), was initiated. Serial echocardiographic examinations over the next 4 days revealed that the left ventricular systolic function completely normalized, and troponin T and NT-proBNP level considerably decreased (228 ng/L and 1190 ng/L, respectively). ECG showing sinus rhythm, rate 82/min with a vertical axis, did not indicate myocardial ischemia. Based on troponin T and NT-proBNP levels, echocardiographic findings, ECG, and clinical restitution, the patient was diagnosed with takotsubo cardiomyopathy. He was then transferred back to the psychiatric department. At that time, clopidogrel was discontinued as the diagnosis of myocardial infarction seemed unlikely. During the next two weeks, echocardiographic exams were unremarkable, and troponin T and NT-proBNP levels were within the reference range (6 ng/L and 69 ng/L, respectively). By the end of week 12, the patient was referred to a chronic psychiatric institution.

Discussion
==========

Our hypothesis was that in our patient clozapine and ECT induced catecholamine activity discordant with beta-blocker effect. Of the 16 reported ECT-induced takotsubo cardiomyopathy cases so far, only one was a young male patient treated with clozapine, but without concomitant beta-blocker therapy ([Table 1](#T1){ref-type="table"}) ([@R2]-[@R16]).

###### 

Case studies about Takotsubo cardiomyopathy after the use of electroconvulsive therapy (ECT) ordered by the year of publishing.

                            Sex   Ethnicity   Age   Diagnose                                                      Main therapy                                                                       Concomitant therapy                                                                                                       Number of ECT applications                                           Comorbidities                                                                                                      Alcohol/tobacco/illicit drugs use
  ------------------------- ----- ----------- ----- ------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -----------------------------------
  Zhu 1992 (6)              F     Unknown     77    Major depression                                              Antidepressant therapy                                                             Unknown                                                                                                                   Not specified, 1st?                                                  No history of cardiac disease                                                                                      Unknown
  Eitzman 1994 (7)          F     Unknown     76    Severe depression                                             Unknown                                                                            Unknown                                                                                                                   Unknown                                                              No history of medical treatment                                                                                    Unknown
  Ring 1996 (8)             F     Unknown     41    Major depressive dissociative disorder                        Paroxetine 80 mg daily, naltrexone 200 mg daily                                    Propranolol long-acting 800 mg, propranolol 30 mg four times daily                                                        1st course; 1st session                                              Obesity                                                                                                            Unknown
  O'Reardon 2008 (16)       F     Unknown     45    Major depressive disorder                                     Unknown                                                                            Warfarin                                                                                                                  1st course: 3rd session                                              Deep vein thrombosis with multiple pulmonary emboli, obstructive sleep apnea, hypertension, Loeys-Dietz syndrome   None
  Chandra 2009 (12)         F     Unknown     70    Depression, bipolar disorder                                  Unknown                                                                            Unknown                                                                                                                   Unknown                                                              Mitral valve prolapse repair                                                                                       Unknown
  Go 2009 (9)               F     Unknown     50    Major depression with suicidal ideation                       Quetiapine, venlafaxine, mirtazapine, pregabalin                                   Ropinirole, metformin, insulin, enalapril, hydroxyzine, fexofenadine, aspirin, furosemide                                 Unknown course; 3rd session                                          Type 2 diabetes mellitus, hypertension, obesity, asthma, sleep apnea, degenerative joint disease                   Unknown
  Go 2009 (9)               F     Unknown     49    Bipolar disorder; a depressed state with psychotic features   Valproate, fluoxetine, haloperidol, quetiapine                                     Albuterol, fluticasone/salmeterol                                                                                         Unknown                                                              Asthma, obesity, dyslipidemia, stress incontinence, impaired glucose tolerance                                     Unknown
  Kent 2009 (13)            F     White       71    The major depressive episode with psychotic features          Nortriptyline 25 mg daily, quetiapine 200 mg daily, lorazepam 0.5 mg twice daily   Metoprolol extended-release 100 mg twice daily, amlodipine 5 mg twice daily, Nonsteroidal anti-inflammatory medications   3rd course; 3rd session                                              Hypertension, costochondritis                                                                                      Unknown
  Satterthwaite 2009 (10)   F     White       72    Major depression with catatonia                               Unknown                                                                            Unknown                                                                                                                   1st course; 1st session                                              Unknown                                                                                                            Unknown
  Beach 2010 (1)            F     White       52    Treatment-resistant depression                                Fluoxetine 80 mg daily, olanzapine 5 mg daily                                      Topiramate 200 mg daily, gabapentin 800 mg daily                                                                          Not specified, 1st?                                                  Migraine headaches, cholecystectomy                                                                                Occasional alcohol use
  Serby 2010 (5)            F     White       90    The recurrent major depressive disorder                       Duloxetine 60 mg daily                                                             Ranitidine 150 mg daily, calcium carbonate 600 mg twice daily, multivitamin once daily                                    \>100 courses of ECT; mECT\* for more than five years; 3rd session   Hypertension (normotensive without medication)                                                                     Unknown
  Celano 2011 (14)          F     Unknown     76    The recurrent major depressive disorder                       Mirtazapine, olanzapine                                                            Unknown                                                                                                                   1st course; 11 sessions (1st mECT\* session)                         Multiple myelomas                                                                                                  Unknown
  Binhas 2013 (11)          F     Unknown     85    Depression, anorexia                                          Unknown                                                                            Unknown                                                                                                                   Unknown course; 3rd session                                          Unknown                                                                                                            Unknown
  Grubisha 2014 (3)         M     Unknown     31    Schizoaffective disorder, pervasive developmental disease     Clozapine 350 mg daily                                                             Zonisamide                                                                                                                2nd course; 50 treatments                                            Hypertension, seizure disorder                                                                                     Unknown
  Narayanan 2014 (15)       F     White       74    The recurrent major depressive disorder                       Venlafaxine, mirtazapine, lithium, aripiprazole                                    Bisoprolol 2.5 mg/daily, lisinopril 20 mg/daily                                                                           2nd course; 1st session                                              Chronic obstructive pulmonary disease, hypertension                                                                None
  De Wolf 2015 (4)          F     Unknown     67    The recurrent major depressive disorder                       Fluvoxamine 300 mg daily, mirtazapine 15 mg daily                                  Unknown                                                                                                                   Unknown (2nd?); 24 sessions (mECT\*)                                 Oropharyngeal cancer                                                                                               Unknown

\*mECT -- maintenance electroconvulsive therapy.

Although ECT-related cardiac complications have been occasionally reported, takotsubo cardiomyopathy remains the least understood among them. Takotsubo cardiomyopathy is a transient cardiac syndrome that most often involves left ventricular apical akinesis and mimics acute coronary syndrome, showing ST-segment elevation and cardiac enzyme levels similar to myocardial infarction ([@R17]). However, in takotsubo cardiomyopathy cardiac angiography can confirm no significant coronary artery stenosis. Typical echocardiography reveals left ventricular apical ballooning ([@R17]). Several takotsubo cardiomyopathy causes have been proposed, including coronary artery ischemia and microvascular spasm ([@R18]). The spasm is induced by a sudden catecholamine increase since patients with takotsubo cardiomyopathy have elevated catecholamine blood concentrations. Takotsubo cardiomyopathy was also strongly associated with mental illnesses ([@R19]). Although our patient did not undergo angiography, we find takotsubo cardiomyopathy a more likely diagnosis than ST-elevation myocardial infarction for several reasons. The degree of ECG changes observed in the initial ECG, along with a severely reduced left ventricular ejection fraction, would not likely resolve in 24 hours in a patient with conservatively treated ST elevation myocardial infarction. Furthermore, troponin T peak of \<2000 ng/L is rarely observed in cases of anterior myocardial infarction, even when timely reperfusion is performed. The patient could have stable coronary disease due to his significant history of nicotine abuse, which might have temporarily worsened ischemia. However, he never complained of chest pain, either before or after the described event. Moreover, it is unlikely that transient spasm would cause such echocardiographic findings ([@R20]). Lastly, deep, symmetric T wave inversion and prolonged QTc interval observed in this case are prominent features of takotsubo cardiomyopathy ([@R17]).

Most patients with ECT-induced takotsubo cardiomyopathy were women older than 70 treated for major depression ([@R4]-[@R7],[@R10],[@R11],[@R14]). Due to hormonal changes, post-menopausal women could be more susceptible to cardiovascular events after a sympathetic response to acute stressors, such as ECT application ([@R18]). However, men show a greater autonomic response to stress than pre-menopausal women of the same age ([@R21]). Psychosis has been associated with catecholamine dysfunction, and excessive psychological stress with long-term norepinephrine dysfunction ([@R22]). Therefore, positive psychotic symptoms in our patient could have led to elevated catecholamine blood concentrations.

Grubisha et al ([@R16]) reported on a case of takotsubo cardiomyopathy after concomitant ECT and clozapine use, which points to a synergistic effect of ECT and clozapine. Clozapine is a strong antagonist of different subtypes of adrenergic, cholinergic, and histaminergic receptors and systematically elevates epinephrine and norepinephrine levels. Catecholamine hypothesis of ECT-induced takotsubo cardiomyopathy is supported by the burst activity of norepinephrine neurons not only due to ECT, but also due to clozapine and nicotine use, as was shown in the locus coeruleus in an animal model ([@R23]). How these therapies interact to alter levels of catecholamine remains unclear. Reports on ECT-induced takotsubo cardiomyopathy show that antidepressants alter the neuronal reuptake of plasma catecholamine and facilitate myocardial stunning by increasing local catecholamine levels ([Table 1](#T1){ref-type="table"}).

Adrenergic blockade before, during, and after ECT minimizes the risk of takotsubo cardiomyopathy recurrence ([@R5]). There are a few patients who underwent successful retrials of ECT after having developed takotsubo cardiomyopathy ([@R6]). Takotsubo cardiomyopathy treatment includes beta blockers during the period of ventricular recovery ([@R18]), and beta blockers have been shown in animal models to improve left ventricular ejection fraction ([@R24]). There are three reports on the concomitant use of beta blockers in patients who develop takotsubo cardiomyopathy, similar to our case ([@R5],[@R7],[@R12]). Patients may be predisposed to develop takotsubo cardiomyopathy by conditions that raise baseline catecholamine level ([@R17],[@R19]). Both caffeine and nicotine elevate catecholamine blood levels ([@R25]), and our patient's caffeine and nicotine use could have precipitated a cardiovascular accident. In this case, simultaneous effects of clozapine, caffeine, nicotine, and ECT, along with male sex, seem to have overpowered the protective effect of beta blockers on takotsubo cardiomyopathy development.

In conclusion, our case shows that takotsubo cardiomyopathy can occur as a rare complication of ECT in a male psychotic patient, despite the concomitant beta-blockade treatment. Clinical understanding of rare cardiac ECT complications could improve early recognition of patients at risk for takotsubo cardiomyopathy and ensure safe ECT protocols.
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